Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.